Press Release – Lille, December 4th, 2025

StarkAge Therapeutics Strengthens Leadership with Appointment of Dr. Florence Lhospice as Executive President and Dr. Éric Angevin as Chief Medical Officer

• Reinforcing StarkAge’s transition toward IND-enabling and early clinical development for STX-1
• Florence Lhospice, PharmD, PhD, brings ADC and CMC expertise as well as a strategic leadership to advance Starkage pipeline
• Eric Angevin, MD, PhD, seasoned early-development oncologist, adds rare, direct clinical expertise in DPP4-targeted therapies

Lille, France – December 4, 2025 – StarkAge Therapeutics, a biotechnology company developing first-in-class senolytic antibody-drug conjugates (ADC) in age-related diseases with an initial focus on oncology, today announced the appointment of Florence Lhospice, PharmD, PhD, as Executive President and Éric Angevin, MD, PhD, as Chief Medical Officer.

These appointments come as StarkAge prepares to advance its lead senolytic ADC, STX-1, into IND-enabling studies and toward early clinical development in solid tumors.

Benjamin Le Calvé, Chief Executive Officer of StarkAge Therapeutics, stated: “We are delighted to welcome Florence and Éric to the team. Their complementary expertise, from ADC development to clinical oncology, combined with experience spanning academia, biotech, and industry partnerships, will be instrumental as we transition STX-1 into IND-enabling activities and shape the next phase of StarkAge’s growth.”

Florence Lhospice is widely recognized as an expert in ADCs, with significant leadership roles at both Innate Pharma and Emergence Therapeutics. At Innate Pharma, she advanced site-specific conjugation technologies, improving ADC homogeneity and therapeutic index, and contributed to the development of multiple oncology assets. As Chief Development Officer at Emergence Therapeutics, she continued to push forward innovative ADC technologies until the company’s acquisition by Eli Lilly in 2023. Throughout her career, she brought multiple programs to IND and currently collaborates with multiple companies across ADC development, fund raising and M&A.

Florence Lhospice commented: “StarkAge is uniquely positioned at the convergence of senescence biology, cancer and ADC innovation. I am very excited to join such an innovative company with the potential to deliver a new class of transformative therapies to patients with high unmet need.”

Dr Eric Angevin brings more than 20 years of experience in early-phase clinical development at Gustave Roussy, the leading Europe’s comprehensive and largest cancer center. Since 2006, he has led industrial partnerships and collaborations, while serving as a senior investigator within the Drug Development Department (DITEP). Over his career, Dr Angevin has led or contributed to more than 300 clinical trials, including multiple first-in-human studies using monoclonal antibodies/ADCs, immunotherapies and precision medicine programs. Importantly, he has already conducted the clinical evaluation of an anti-DPP4 antibody, directly aligning with StarkAge’s therapeutic focus. He is also an active member of the ASCO, AACR, ESMO, and TAT communities.

Dr. Angevin commented: “The harmful effect of senescence is now well recognized in cancers. Targeting senescent tumor cells, and specifically DPP4, is supported by strong rationale and could have important implications for the single-cell biology and treatments of many refractory cancers. Having previously overseen a clinical trial with an anti-DPP4 antibody, I clearly see the therapeutic potential of this target. STX-1 program is well positioned to address key mechanisms of resistance, metastatic progression, and immune dysfunction in solid tumors.”